NetWalker: a Contextual Network Analysis Tool for Functional Genomics
Overview
Affiliations
Background: Functional analyses of genomic data within the context of a priori biomolecular networks can give valuable mechanistic insights. However, such analyses are not a trivial task, owing to the complexity of biological networks and lack of computational methods for their effective integration with experimental data.
Results: We developed a software application suite, NetWalker, as a one-stop platform featuring a number of novel holistic (i.e. assesses the whole data distribution without requiring data cutoffs) data integration and analysis methods for network-based comparative interpretations of genome-scale data. The central analysis components, NetWalk and FunWalk, are novel random walk-based network analysis methods that provide unique analysis capabilities to assess the entire data distributions together with network connectivity to prioritize molecular and functional networks, respectively, most highlighted in the supplied data. Extensive inter-operability between the analysis components and with external applications, including R, adds to the flexibility of data analyses. Here, we present a detailed computational analysis of our microarray gene expression data from MCF7 cells treated with lethal and sublethal doses of doxorubicin.
Conclusion: NetWalker, a detailed step-by-step tutorial containing the analyses presented in this paper and a manual are available at the web site http://netwalkersuite.org.
Multilayer Analysis of RNA Sequencing Data in Alzheimer's Disease to Unravel Molecular Mysteries.
Uzuner D, Ilgun A, Duz E, Bozkurt F, Cakir T Adv Neurobiol. 2024; 41:219-246.
PMID: 39589716 DOI: 10.1007/978-3-031-69188-1_9.
Role of Artificial Intelligence in Drug Discovery and Target Identification in Cancer.
Sharma V, Singh A, Chauhan S, Sharma P, Chaudhary S, Sharma A Curr Drug Deliv. 2023; 21(6):870-886.
PMID: 37670704 DOI: 10.2174/1567201821666230905090621.
Handley K, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E Mol Cancer Ther. 2021; 20(12):2352-2361.
PMID: 34583979 PMC: 8643313. DOI: 10.1158/1535-7163.MCT-21-0370.
MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala L Gynecol Oncol. 2021; 163(1):181-190.
PMID: 34391578 PMC: 8511168. DOI: 10.1016/j.ygyno.2021.08.003.
Guebel D, Torres N, Acebes A Biol Open. 2021; 10(5).
PMID: 34184731 PMC: 8181899. DOI: 10.1242/bio.057950.